25 XP   0   0   10

Lytix Biopharma AS
Buy, Hold or Sell?

Let's analyse Lytix Biopharma AS together

PenkeI guess you are interested in Lytix Biopharma AS. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Lytix Biopharma AS. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Lytix Biopharma AS

I send you an email if I find something interesting about Lytix Biopharma AS.

Quick analysis of Lytix Biopharma AS (30 sec.)










What can you expect buying and holding a share of Lytix Biopharma AS? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr3.37
Expected worth in 1 year
kr-2.07
How sure are you?
66.7%

+ What do you gain per year?

Total Gains per Share
kr-5.44
Return On Investment
-98.9%

For what price can you sell your share?

Current Price per Share
kr5.50
Expected price per share
kr4.6 - kr8.8
How sure are you?
50%

1. Valuation of Lytix Biopharma AS (5 min.)




Live pricePrice per Share (EOD)

kr5.50

Intrinsic Value Per Share

kr-13.23 - kr-4.72

Total Value Per Share

kr-9.86 - kr-1.35

2. Growth of Lytix Biopharma AS (5 min.)




Is Lytix Biopharma AS growing?

Current yearPrevious yearGrowGrow %
How rich?$12.2m$17.1m-$4.9m-40.3%

How much money is Lytix Biopharma AS making?

Current yearPrevious yearGrowGrow %
Making money-$5m-$4.3m-$720.9k-14.2%
Net Profit Margin-3,974.9%-282,641.2%--

How much money comes from the company's main activities?

3. Financial Health of Lytix Biopharma AS (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#663 / 1016

Most Revenue
#627 / 1016

Most Profit
#426 / 1016

Most Efficient
#895 / 1016

What can you expect buying and holding a share of Lytix Biopharma AS? (5 min.)

Welcome investor! Lytix Biopharma AS's management wants to use your money to grow the business. In return you get a share of Lytix Biopharma AS.

What can you expect buying and holding a share of Lytix Biopharma AS?

First you should know what it really means to hold a share of Lytix Biopharma AS. And how you can make/lose money.

Speculation

The Price per Share of Lytix Biopharma AS is kr5.5. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Lytix Biopharma AS.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Lytix Biopharma AS, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr3.37. Based on the TTM, the Book Value Change Per Share is kr-1.36 per quarter. Based on the YOY, the Book Value Change Per Share is kr4.24 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Lytix Biopharma AS.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps-0.13-2.3%-0.13-2.3%-0.11-2.0%-0.11-2.0%-0.11-2.1%
Usd Book Value Change Per Share-0.12-2.2%-0.12-2.2%0.387.0%0.061.0%0.050.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.12-2.2%-0.12-2.2%0.387.0%0.061.0%0.050.9%
Usd Price Per Share0.70-0.70-1.25-0.39-0.32-
Price to Earnings Ratio-5.55--5.55--11.47--3.40--2.84-
Price-to-Total Gains Ratio-5.71--5.71-3.25--1.23--1.23-
Price to Book Ratio2.30-2.30-2.91-1.04-0.87-
Price-to-Total Gains Ratio-5.71--5.71-3.25--1.23--1.23-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.4983
Number of shares2006
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.120.06
Usd Total Gains Per Share-0.120.06
Gains per Quarter (2006 shares)-247.19111.89
Gains per Year (2006 shares)-988.78447.55
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-989-9990448438
20-1978-19880895886
30-2966-2977013431334
40-3955-3966017901782
50-4944-4955022382230
60-5933-5944026852678
70-6921-6933031333126
80-7910-7922035803574
90-8899-8911040284022
100-9888-9900044754470

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.06.00.00.0%0.06.00.00.0%
Book Value Change Per Share0.01.00.00.0%2.01.00.066.7%3.02.00.060.0%4.02.00.066.7%4.02.00.066.7%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.06.00.0%0.00.06.00.0%
Total Gains per Share0.01.00.00.0%2.01.00.066.7%3.02.00.060.0%4.02.00.066.7%4.02.00.066.7%

Fundamentals of Lytix Biopharma AS

About Lytix Biopharma AS

Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials. The company's products also include LTX-401, an oncolytic molecule for targeting deep-seated lesions, such as liver cancer and is in a preclinical phase. The company was incorporated in 2003 and is based in Oslo, Norway.

Fundamental data was last updated by Penke on 2024-03-30 23:28:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Lytix Biopharma AS.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Lytix Biopharma AS earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Lytix Biopharma AS to the Biotechnology industry mean.
  • A Net Profit Margin of -3,974.9% means that kr-39.75 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Lytix Biopharma AS:

  • The MRQ is -3,974.9%. The company is making a huge loss. -2
  • The TTM is -3,974.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-3,974.9%TTM-3,974.9%0.0%
TTM-3,974.9%YOY-282,641.2%+278,666.3%
TTM-3,974.9%5Y-343,704.3%+339,729.4%
5Y-343,704.3%10Y-287,417.4%-56,286.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3,974.9%-197.2%-3,777.7%
TTM-3,974.9%-210.4%-3,764.5%
YOY-282,641.2%-279.3%-282,361.9%
5Y-343,704.3%-436.8%-343,267.5%
10Y-287,417.4%-599.3%-286,818.1%
1.1.2. Return on Assets

Shows how efficient Lytix Biopharma AS is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Lytix Biopharma AS to the Biotechnology industry mean.
  • -36.8% Return on Assets means that Lytix Biopharma AS generated kr-0.37 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Lytix Biopharma AS:

  • The MRQ is -36.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -36.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-36.8%TTM-36.8%0.0%
TTM-36.8%YOY-23.7%-13.2%
TTM-36.8%5Y-96.9%+60.1%
5Y-96.9%10Y-103.2%+6.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-36.8%-13.6%-23.2%
TTM-36.8%-12.9%-23.9%
YOY-23.7%-11.9%-11.8%
5Y-96.9%-14.2%-82.7%
10Y-103.2%-16.2%-87.0%
1.1.3. Return on Equity

Shows how efficient Lytix Biopharma AS is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Lytix Biopharma AS to the Biotechnology industry mean.
  • -41.4% Return on Equity means Lytix Biopharma AS generated kr-0.41 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Lytix Biopharma AS:

  • The MRQ is -41.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -41.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-41.4%TTM-41.4%0.0%
TTM-41.4%YOY-25.3%-16.1%
TTM-41.4%5Y-134.6%+93.1%
5Y-134.6%10Y-201.7%+67.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-41.4%-17.0%-24.4%
TTM-41.4%-16.1%-25.3%
YOY-25.3%-15.4%-9.9%
5Y-134.6%-20.0%-114.6%
10Y-201.7%-21.1%-180.6%

1.2. Operating Efficiency of Lytix Biopharma AS.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Lytix Biopharma AS is operating .

  • Measures how much profit Lytix Biopharma AS makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Lytix Biopharma AS to the Biotechnology industry mean.
  • An Operating Margin of -4,662.6% means the company generated kr-46.63  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Lytix Biopharma AS:

  • The MRQ is -4,662.6%. The company is operating very inefficient. -2
  • The TTM is -4,662.6%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-4,662.6%TTM-4,662.6%0.0%
TTM-4,662.6%YOY-282,447.1%+277,784.5%
TTM-4,662.6%5Y-345,781.4%+341,118.8%
5Y-345,781.4%10Y-289,382.8%-56,398.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4,662.6%-286.1%-4,376.5%
TTM-4,662.6%-224.4%-4,438.2%
YOY-282,447.1%-288.4%-282,158.7%
5Y-345,781.4%-475.2%-345,306.2%
10Y-289,382.8%-624.7%-288,758.1%
1.2.2. Operating Ratio

Measures how efficient Lytix Biopharma AS is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 47.63 means that the operating costs are kr47.63 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Lytix Biopharma AS:

  • The MRQ is 47.626. The company is inefficient in keeping operating costs low. -1
  • The TTM is 47.626. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ47.626TTM47.6260.000
TTM47.626YOY2,825.471-2,777.845
TTM47.6265Y3,458.814-3,411.188
5Y3,458.81410Y2,882.345+576.469
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ47.6262.997+44.629
TTM47.6263.247+44.379
YOY2,825.4713.766+2,821.705
5Y3,458.8145.675+3,453.139
10Y2,882.3457.857+2,874.488

1.3. Liquidity of Lytix Biopharma AS.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Lytix Biopharma AS is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 8.99 means the company has kr8.99 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Lytix Biopharma AS:

  • The MRQ is 8.993. The company is very able to pay all its short-term debts. +2
  • The TTM is 8.993. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ8.993TTM8.9930.000
TTM8.993YOY15.217-6.224
TTM8.9935Y6.919+2.073
5Y6.91910Y5.988+0.931
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.9933.930+5.063
TTM8.9934.251+4.742
YOY15.2175.436+9.781
5Y6.9196.045+0.874
10Y5.9886.363-0.375
1.3.2. Quick Ratio

Measures if Lytix Biopharma AS is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Lytix Biopharma AS to the Biotechnology industry mean.
  • A Quick Ratio of 11.94 means the company can pay off kr11.94 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Lytix Biopharma AS:

  • The MRQ is 11.945. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 11.945. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ11.945TTM11.9450.000
TTM11.945YOY15.176-3.231
TTM11.9455Y7.465+4.480
5Y7.46510Y6.442+1.023
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.9453.629+8.316
TTM11.9454.065+7.880
YOY15.1765.397+9.779
5Y7.4655.993+1.472
10Y6.4426.277+0.165

1.4. Solvency of Lytix Biopharma AS.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Lytix Biopharma AS assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Lytix Biopharma AS to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.11 means that Lytix Biopharma AS assets are financed with 11.1% credit (debt) and the remaining percentage (100% - 11.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Lytix Biopharma AS:

  • The MRQ is 0.111. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.111. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.111TTM0.1110.000
TTM0.111YOY0.066+0.045
TTM0.1115Y0.218-0.107
5Y0.21810Y0.307-0.089
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1110.332-0.221
TTM0.1110.334-0.223
YOY0.0660.268-0.202
5Y0.2180.366-0.148
10Y0.3070.390-0.083
1.4.2. Debt to Equity Ratio

Measures if Lytix Biopharma AS is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Lytix Biopharma AS to the Biotechnology industry mean.
  • A Debt to Equity ratio of 12.5% means that company has kr0.13 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Lytix Biopharma AS:

  • The MRQ is 0.125. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.125. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.125TTM0.1250.000
TTM0.125YOY0.070+0.055
TTM0.1255Y0.311-0.186
5Y0.31110Y0.758-0.447
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1250.381-0.256
TTM0.1250.390-0.265
YOY0.0700.334-0.264
5Y0.3110.434-0.123
10Y0.7580.466+0.292

2. Market Valuation of Lytix Biopharma AS

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Lytix Biopharma AS generates.

  • Above 15 is considered overpriced but always compare Lytix Biopharma AS to the Biotechnology industry mean.
  • A PE ratio of -5.55 means the investor is paying kr-5.55 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Lytix Biopharma AS:

  • The EOD is -3.935. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.552. Based on the earnings, the company is expensive. -2
  • The TTM is -5.552. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.935MRQ-5.552+1.617
MRQ-5.552TTM-5.5520.000
TTM-5.552YOY-11.466+5.914
TTM-5.5525Y-3.404-2.148
5Y-3.40410Y-2.836-0.567
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.935-2.315-1.620
MRQ-5.552-2.560-2.992
TTM-5.552-2.664-2.888
YOY-11.466-4.122-7.344
5Y-3.404-6.258+2.854
10Y-2.836-6.108+3.272
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Lytix Biopharma AS:

  • The EOD is -4.217. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -5.950. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -5.950. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.217MRQ-5.950+1.733
MRQ-5.950TTM-5.9500.000
TTM-5.950YOY-12.271+6.321
TTM-5.9505Y-3.644-2.306
5Y-3.64410Y-3.037-0.607
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.217-3.067-1.150
MRQ-5.950-3.251-2.699
TTM-5.950-3.545-2.405
YOY-12.271-5.595-6.676
5Y-3.644-8.315+4.671
10Y-3.037-8.708+5.671
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Lytix Biopharma AS is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.30 means the investor is paying kr2.30 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Lytix Biopharma AS:

  • The EOD is 1.631. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.301. Based on the equity, the company is underpriced. +1
  • The TTM is 2.301. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.631MRQ2.301-0.670
MRQ2.301TTM2.3010.000
TTM2.301YOY2.905-0.604
TTM2.3015Y1.041+1.260
5Y1.04110Y0.868+0.174
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.6311.905-0.274
MRQ2.3012.111+0.190
TTM2.3012.095+0.206
YOY2.9052.836+0.069
5Y1.0413.443-2.402
10Y0.8683.794-2.926
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Lytix Biopharma AS compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.360-1.3600%4.236-132%0.616-321%0.562-342%
Book Value Per Share--3.3723.3720%4.733-29%1.993+69%1.710+97%
Current Ratio--8.9938.9930%15.217-41%6.919+30%5.988+50%
Debt To Asset Ratio--0.1110.1110%0.066+69%0.218-49%0.307-64%
Debt To Equity Ratio--0.1250.1250%0.070+78%0.311-60%0.758-84%
Dividend Per Share----0%-0%-0%-0%
Eps---1.398-1.3980%-1.199-14%-1.202-14%-1.266-9%
Free Cash Flow Per Share---1.304-1.3040%-1.120-14%-1.153-12%-1.250-4%
Free Cash Flow To Equity Per Share---1.301-1.3010%4.214-131%0.550-336%0.531-345%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---4.724--------
Intrinsic Value_10Y_min---13.231--------
Intrinsic Value_1Y_max---0.897--------
Intrinsic Value_1Y_min---1.209--------
Intrinsic Value_3Y_max---2.372--------
Intrinsic Value_3Y_min---3.754--------
Intrinsic Value_5Y_max---3.458--------
Intrinsic Value_5Y_min---6.415--------
Market Cap220375650.000-41%310930163.200310930163.2000%550939125.000-44%172373857.640+80%143644881.367+116%
Net Profit Margin---39.749-39.7490%-2826.412+7011%-3437.043+8547%-2874.174+7131%
Operating Margin---46.626-46.6260%-2824.471+5958%-3457.814+7316%-2893.828+6106%
Operating Ratio--47.62647.6260%2825.471-98%3458.814-99%2882.345-98%
Pb Ratio1.631-41%2.3012.3010%2.905-21%1.041+121%0.868+165%
Pe Ratio-3.935+29%-5.552-5.5520%-11.466+107%-3.404-39%-2.836-49%
Price Per Share5.500-41%7.7607.7600%13.750-44%4.302+80%3.585+116%
Price To Free Cash Flow Ratio-4.217+29%-5.950-5.9500%-12.271+106%-3.644-39%-3.037-49%
Price To Total Gains Ratio-4.044+29%-5.705-5.7050%3.246-276%-1.230-78%-1.230-78%
Quick Ratio--11.94511.9450%15.176-21%7.465+60%6.442+85%
Return On Assets---0.368-0.3680%-0.237-36%-0.969+163%-1.032+180%
Return On Equity---0.414-0.4140%-0.253-39%-1.346+225%-2.017+387%
Total Gains Per Share---1.360-1.3600%4.236-132%0.616-321%0.562-342%
Usd Book Value--12242415.60012242415.6000%17179934.400-29%7234754.280+69%6206990.900+97%
Usd Book Value Change Per Share---0.123-0.1230%0.384-132%0.056-321%0.051-342%
Usd Book Value Per Share--0.3060.3060%0.429-29%0.181+69%0.155+97%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.127-0.1270%-0.109-14%-0.109-14%-0.115-9%
Usd Free Cash Flow---4734393.600-4734393.6000%-4067577.600-14%-4184542.200-12%-4539150.600-4%
Usd Free Cash Flow Per Share---0.118-0.1180%-0.102-14%-0.104-12%-0.113-4%
Usd Free Cash Flow To Equity Per Share---0.118-0.1180%0.382-131%0.050-336%0.048-345%
Usd Market Cap19966033.890-41%28170272.78628170272.7860%49915084.725-44%15617071.502+80%13014226.252+116%
Usd Price Per Share0.498-41%0.7030.7030%1.246-44%0.390+80%0.325+116%
Usd Profit---5074143.600-5074143.6000%-4353239.400-14%-4364836.200-14%-4594039.100-9%
Usd Revenue--127655.400127655.4000%1540.200+8188%37617.120+239%47338.500+170%
Usd Total Gains Per Share---0.123-0.1230%0.384-132%0.056-321%0.051-342%
 EOD+3 -5MRQTTM+0 -0YOY+6 -275Y+18 -1510Y+18 -15

3.2. Fundamental Score

Let's check the fundamental score of Lytix Biopharma AS based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.935
Price to Book Ratio (EOD)Between0-11.631
Net Profit Margin (MRQ)Greater than0-39.749
Operating Margin (MRQ)Greater than0-46.626
Quick Ratio (MRQ)Greater than111.945
Current Ratio (MRQ)Greater than18.993
Debt to Asset Ratio (MRQ)Less than10.111
Debt to Equity Ratio (MRQ)Less than10.125
Return on Equity (MRQ)Greater than0.15-0.414
Return on Assets (MRQ)Greater than0.05-0.368
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Lytix Biopharma AS based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.492
Ma 20Greater thanMa 506.168
Ma 50Greater thanMa 1006.285
Ma 100Greater thanMa 2006.181
OpenGreater thanClose5.420
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in NOK. All numbers in thousands.

Summary
Total Assets152,017
Total Liabilities16,891
Total Stockholder Equity135,126
 As reported
Total Liabilities 16,891
Total Stockholder Equity+ 135,126
Total Assets = 152,017

Assets

Total Assets152,017
Total Current Assets151,893
Long-term Assets124
Total Current Assets
Cash And Cash Equivalents 94,552
Short-term Investments 50,606
Net Receivables 5,998
Total Current Assets  (as reported)151,893
Total Current Assets  (calculated)151,156
+/- 737
Long-term Assets
Property Plant Equipment 124
Long-term Assets  (as reported)124
Long-term Assets  (calculated)124
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities16,891
Long-term Liabilities0
Total Stockholder Equity135,126
Total Current Liabilities
Accounts payable 6,997
Other Current Liabilities 9,894
Total Current Liabilities  (as reported)16,891
Total Current Liabilities  (calculated)16,891
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock4,007
Capital Surplus 131,119
Total Stockholder Equity (as reported)135,126
Total Stockholder Equity (calculated)135,126
+/-0
Other
Capital Stock4,007
Cash And Equivalents94,552
Cash and Short Term Investments 145,158
Common Stock Shares Outstanding 40,068
Liabilities and Stockholders Equity 152,017
Net Invested Capital 135,126
Net Tangible Assets 135,126
Net Working Capital 135,002
Property Plant and Equipment Gross 154



Balance Sheet

Currency in NOK. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
> Total Assets 
47,092
58,900
17,434
32,617
202,962
152,017
152,017202,96232,61717,43458,90047,092
   > Total Current Assets 
47,086
58,900
17,434
32,617
202,962
151,893
151,893202,96232,61717,43458,90047,086
       Cash And Cash Equivalents 
34,957
48,871
12,046
27,150
197,282
94,552
94,552197,28227,15012,04648,87134,957
       Short-term Investments 
0
0
0
0
0
50,606
50,60600000
       Net Receivables 
11,967
8,813
4,193
3,632
5,132
5,998
5,9985,1323,6324,1938,81311,967
       Other Current Assets 
0
1
0
-1
-1
0
0-1-1010
   > Long-term Assets 
0
0
0
0
0
124
12400000
       Property Plant Equipment 
6
0
0
0
0
124
12400006
> Total Liabilities 
35,302
17,850
3,854
12,728
13,338
16,891
16,89113,33812,7283,85417,85035,302
   > Total Current Liabilities 
35,301
17,849
3,854
12,728
13,338
16,891
16,89113,33812,7283,85417,84935,301
       Accounts payable 
11,652
13,184
0
3,284
1,476
6,997
6,9971,4763,284013,18411,652
       Other Current Liabilities 
22,111
1,270
1,717
4,811
8,090
9,894
9,8948,0904,8111,7171,27022,111
   > Long-term Liabilities 
0
1
0
0
0
0
000010
       Other Liabilities 
0
1
0
0
0
0
000010
> Total Stockholder Equity
11,790
41,050
13,580
19,889
189,624
135,126
135,126189,62419,88913,58041,05011,790
   Common Stock
1,234
2,249
2,289
2,623
3,874
4,007
4,0073,8742,6232,2892,2491,234
   Retained Earnings Total Equity000000
   Accumulated Other Comprehensive Income 000000
   Capital Surplus 
10,557
34,801
11,291
17,266
185,750
131,119
131,119185,75017,26611,29134,80110,557
   Treasury Stock000000
   Other Stockholders Equity 
-1
4,001
0
0
0
0
00004,001-1



Balance Sheet

Currency in NOK. All numbers in thousands.




Cash Flow

Currency in NOK. All numbers in thousands.




Income Statement

Currency in NOK. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue3,991
Cost of Revenue--
Gross Profit-3,991
 
Operating Income (+$)
Gross Profit-
Operating Expense-105,103
Operating Income-101,112-105,103
 
Operating Expense (+$)
Research Development67,841
Selling General Administrative-
Selling And Marketing Expenses-
Operating Expense105,10367,841
 
Net Interest Income (+$)
Interest Income-
Interest Expense--
Other Finance Cost-5,164
Net Interest Income-5,164
 
Pretax Income (+$)
Operating Income-101,112
Net Interest Income-5,164
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-98,551-101,112
EBIT - interestExpense = 0
-98,551
-98,551
Interest Expense-
Earnings Before Interest and Taxes (EBIT)--98,551
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-98,551
Tax Provision--
Net Income From Continuing Ops-98,551-98,551
Net Income-98,551
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-5,164
 

Technical Analysis of Lytix Biopharma AS
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Lytix Biopharma AS. The general trend of Lytix Biopharma AS is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Lytix Biopharma AS's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Lytix Biopharma AS.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 5.45 < 7.15 < 8.8.

The bearish price targets are: 4.6.

Tweet this
Lytix Biopharma AS Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Lytix Biopharma AS. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Lytix Biopharma AS Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Lytix Biopharma AS. The current macd is -0.19942563.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Lytix Biopharma AS price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Lytix Biopharma AS. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Lytix Biopharma AS price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Lytix Biopharma AS Daily Moving Average Convergence/Divergence (MACD) ChartLytix Biopharma AS Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Lytix Biopharma AS. The current adx is 14.39.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Lytix Biopharma AS shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Lytix Biopharma AS Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Lytix Biopharma AS. The current sar is 6.08333322.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Lytix Biopharma AS Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Lytix Biopharma AS. The current rsi is 39.49. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Lytix Biopharma AS Daily Relative Strength Index (RSI) ChartLytix Biopharma AS Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Lytix Biopharma AS. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Lytix Biopharma AS price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Lytix Biopharma AS Daily Stochastic Oscillator ChartLytix Biopharma AS Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Lytix Biopharma AS. The current cci is -136.27422527.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Lytix Biopharma AS Daily Commodity Channel Index (CCI) ChartLytix Biopharma AS Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Lytix Biopharma AS. The current cmo is -28.55756199.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Lytix Biopharma AS Daily Chande Momentum Oscillator (CMO) ChartLytix Biopharma AS Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Lytix Biopharma AS. The current willr is -82.35294118.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Lytix Biopharma AS Daily Williams %R ChartLytix Biopharma AS Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Lytix Biopharma AS.

Lytix Biopharma AS Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Lytix Biopharma AS. The current atr is 0.51504709.

Lytix Biopharma AS Daily Average True Range (ATR) ChartLytix Biopharma AS Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Lytix Biopharma AS. The current obv is 112,052.

Lytix Biopharma AS Daily On-Balance Volume (OBV) ChartLytix Biopharma AS Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Lytix Biopharma AS. The current mfi is 42.09.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Lytix Biopharma AS Daily Money Flow Index (MFI) ChartLytix Biopharma AS Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Lytix Biopharma AS.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-24STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-30RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-31CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-04WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-06WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-18WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-19CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-20WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Lytix Biopharma AS Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Lytix Biopharma AS based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.492
Ma 20Greater thanMa 506.168
Ma 50Greater thanMa 1006.285
Ma 100Greater thanMa 2006.181
OpenGreater thanClose5.420
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Lytix Biopharma AS with someone you think should read this too:
  • Are you bullish or bearish on Lytix Biopharma AS? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Lytix Biopharma AS? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Lytix Biopharma AS

I send you an email if I find something interesting about Lytix Biopharma AS.


Comments

How you think about this?

Leave a comment

Stay informed about Lytix Biopharma AS.

Receive notifications about Lytix Biopharma AS in your mailbox!